- The disease
- Tendon injuries -- including rotator cuff tears and other musculoskeletal tendon defects -- are common conditions that often require surgical repair or reconstruction. Standard surgical techniques use sutures, autografts (tissue taken from the patient), or synthetic scaffolds to restore tendon continuity. Failure or re-tear rates following tendon repair remain a clinical challenge, and there is ongoing interest in biologic augmentation products that may support tissue regeneration at the repair site.
- What the asset is trying to do
- CelGro is a collagen-based regenerative biologic scaffold manufactured by Orthocell (ASX: OCC). It is derived from purified collagen and is designed to act as a resorbable matrix that supports the body's own tissue repair process at the tendon repair site. Orthocell states that CelGro is distinct from synthetic meshes and non-resorbable implants in that it is intended to be gradually replaced by the patient's own regenerating tissue. The specific collagen source, processing method, and any additional bioactive components are .
- What the trial is measuring, and why it matters
- As an approved product, CelGro is evaluated in real-world and post-market clinical settings rather than in a pivotal trial with a single primary endpoint. Orthocell has disclosed a real-world study of its Remplir product (a CelGro-based device for rotator cuff repair) reporting a 90% success rate (per ASX announcement, 27 April 2026). The endpoints used in that study -- including the definition of 'success', follow-up duration, and patient population -- are pending review of the full study publication or data disclosure.
- Efficacy benchmarks in this setting
- For arthroscopic rotator cuff repair, re-tear rates reported in peer-reviewed literature vary widely by tear size and patient factors; published systematic reviews have reported overall structural failure rates ranging from approximately 20% to over 50% for large and massive tears, though specific figures depend on the study population and imaging methodology used ( -- cite relevant systematic review or meta-analysis). Collagen scaffold augmentation products and other biologic patches have been evaluated in randomised controlled trials, with outcomes including MRI-confirmed tendon integrity and validated functional scores. CelGro's real-world study figures (per ASX announcement, 27 April 2026) are from a non-randomised, post-market context and are not statistically comparable to outcomes reported in randomised controlled trials of approved products.